N. Antonevich, A. Hancharou, O. Timokhina, E. Rynda, Y. Minich, A. Prokhorov, T. Mokhort, K. Chizh
{"title":"用于人类疾病免疫治疗的新型生物医学细胞产品","authors":"N. Antonevich, A. Hancharou, O. Timokhina, E. Rynda, Y. Minich, A. Prokhorov, T. Mokhort, K. Chizh","doi":"10.29235/1818-9857-2022-2-15-23","DOIUrl":null,"url":null,"abstract":"Cellular therapy develops rapidly throughout the world. The list of diseases of various etiologies that are treated with biomedical cellular products is constantly growing. The Center for Immunology and Allergology was opened in the The Institute of Biophysics and Cell Engineering of National Academy of Science of Belarus in 2021. Since that the developing of new biomedical cell products for the correction of immunopathological conditions was started in collaboration with the Belarusian State Medical University. The technologies for producing of biomedical cellular products based on cytokine-induced killer cells for the treatment of oncological diseases of the urogenital area, tolerogenic dendritic cells for the treatment of type 1 diabetes, and regulatory T lymphocytes for the treatment of sclerosis were developed.","PeriodicalId":250051,"journal":{"name":"Science and Innovations","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New biomedical cell products for immunotherapy of human diseases\",\"authors\":\"N. Antonevich, A. Hancharou, O. Timokhina, E. Rynda, Y. Minich, A. Prokhorov, T. Mokhort, K. Chizh\",\"doi\":\"10.29235/1818-9857-2022-2-15-23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cellular therapy develops rapidly throughout the world. The list of diseases of various etiologies that are treated with biomedical cellular products is constantly growing. The Center for Immunology and Allergology was opened in the The Institute of Biophysics and Cell Engineering of National Academy of Science of Belarus in 2021. Since that the developing of new biomedical cell products for the correction of immunopathological conditions was started in collaboration with the Belarusian State Medical University. The technologies for producing of biomedical cellular products based on cytokine-induced killer cells for the treatment of oncological diseases of the urogenital area, tolerogenic dendritic cells for the treatment of type 1 diabetes, and regulatory T lymphocytes for the treatment of sclerosis were developed.\",\"PeriodicalId\":250051,\"journal\":{\"name\":\"Science and Innovations\",\"volume\":\"2 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Science and Innovations\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29235/1818-9857-2022-2-15-23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science and Innovations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29235/1818-9857-2022-2-15-23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
New biomedical cell products for immunotherapy of human diseases
Cellular therapy develops rapidly throughout the world. The list of diseases of various etiologies that are treated with biomedical cellular products is constantly growing. The Center for Immunology and Allergology was opened in the The Institute of Biophysics and Cell Engineering of National Academy of Science of Belarus in 2021. Since that the developing of new biomedical cell products for the correction of immunopathological conditions was started in collaboration with the Belarusian State Medical University. The technologies for producing of biomedical cellular products based on cytokine-induced killer cells for the treatment of oncological diseases of the urogenital area, tolerogenic dendritic cells for the treatment of type 1 diabetes, and regulatory T lymphocytes for the treatment of sclerosis were developed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
